

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 November 2022 (24.11.2022)



(10) International Publication Number
WO 2022/246039 A1

(51) International Patent Classification:

A61K 31/4168 (2006.01) A61P 9/00 (2006.01)
A61P 1/16 (2006.01) A61P 9/04 (2006.01)
A61P 3/00 (2006.01) A61P 9/10 (2006.01)
A61P 3/04 (2006.01) A61P 9/12 (2006.01)
A61P 3/06 (2006.01) A61P 35/00 (2006.01)
A61P 3/10 (2006.01) A61P 43/00 (2006.01)

(21) International Application Number:

PCT/US2022/029992

(22) International Filing Date:

19 May 2022 (19.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/191,321	20 May 2021 (20.05.2021)	US
63/222,841	16 July 2021 (16.07.2021)	US
63/307,515	07 February 2022 (07.02.2022)	US

(71) Applicant: **RIVUS PHARMACEUTICALS, INC.**
[US/US]: 706B Forest Street, Charlottesville, Virginia
22903 (US).

(72) Inventors: **KHAN, Shaharyar**; 1107 Pike Place, Char-
lottesville, Virginia 22901 (US). **JORKASKY, Diane**; 596
Longchamps Dr., Devon, Pennsylvania 19333 (US).

(74) Agent: **YANG, Lucy**; 650 Trade Centre Way, Suite 200,
Portage, Michigan 49002 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(54) Title: METHODS OF TREATING MITOCHONDRIA-RELATED DISORDERS




FIG. 1

(57) Abstract: Disclosed herein are methods of treatment comprising administering a therapeutically effective amount of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole or a pharmaceutically acceptable salt thereof to a subject in need thereof. 5-[(2,4-Dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole is useful in treating mitochondria-related disorders or conditions including obesity, diabetes, hypertension, cardiovascular disease, and liver diseases.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))